ChromaDex Corporation (NASDAQ:CDXC) and NantKwest Inc. (NASDAQ:NK) are two firms in the Biotechnology that compete against each other. Below is a comparison of their dividends, institutional ownership, analyst recommendations, profitability, risk, earnings and valuation.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
Demonstrates ChromaDex Corporation and NantKwest Inc. earnings per share (EPS), top-line revenue and valuation.
Table 2 hightlights the return on assets, net margins and return on equity of the two companies.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
A 1.25 beta means ChromaDex Corporation’s volatility is 25.00% more than Standard & Poor’s 500’s volatility. Competitively, NantKwest Inc.’s beta is 2.34 which is 134.00% more volatile than Standard & Poor’s 500.
The Current Ratio and Quick Ratio of ChromaDex Corporation are 2.2 and 1.7 respectively. Its competitor NantKwest Inc.’s Current Ratio is 4.1 and its Quick Ratio is 4.1. NantKwest Inc. can pay off short and long-term obligations better than ChromaDex Corporation.
Insider and Institutional Ownership
ChromaDex Corporation and NantKwest Inc. has shares owned by institutional investors as follows: 18.5% and 8.5%. Insiders owned 3.1% of ChromaDex Corporation shares. Insiders Comparatively, owned 21.5% of NantKwest Inc. shares.
In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
For the past year ChromaDex Corporation was more bullish than NantKwest Inc.
NantKwest Inc. beats on 6 of the 10 factors ChromaDex Corporation.
ChromaDex Corporation, a natural products company, discovers, acquires, develops, and commercializes patented and proprietary ingredient technologies. The company offers bulk raw materials for use in dietary supplements, food, beverages, and cosmetic products; Nicotinamide riboside (NIAGEN), a vitamin found naturally in milk for enhancing cardiovascular health, glucose levels, cognitive function, and anti-aging effects; Pterostilbene (pTeroPure), a polyphenol and antioxidant used in health related fields; and Immulina, a spirulina extract and compound, which is used for improving human immune function, as well as developing Pterostilbene and caffeine co-crystal ingredients, and anthocyanins ingredients. It also provides reference standards, materials, and kits to conduct quality control of raw materials and consumer products; and fine chemicals and phytochemicals for research and new product development applications. In addition, the company offers a range of contract services, including routine contract analysis for the production of dietary supplements, cosmetics, foods, and other natural products, as well as elaborate contract research for clients in these industries; and consulting services in the areas of regulatory support, new ingredient or product development, risk management, and litigation support, as well as product regulatory approval and scientific advisory services. Further, it assists customers in creating processes for manufacturing of natural products using green chemistry, as well as developing quality verification seal program, phytochemical libraries, plant extracts libraries, and databases for cross-referencing phytochemicals. The company markets and sells its products directly in the United States and Canada; and through distributors in Europe, China, Japan, South Korea, Brazil, Australia, New Zealand, Taiwan, South Africa, India, Indonesia, Malaysia, Singapore, Thailand, and Mexico. ChromaDex Corporation is based in Irvine, California.
NantKwest, Inc., a clinical-stage immunotherapy biotechnology company, develops immunotherapeutic treatments for cancer, infectious diseases, and inflammatory diseases in the United States. The company develops activated natural killer product candidates for the treatment of virally-induced cancers, such as polyoma virus induced merkel cell carcinoma, human papilloma virus induced cervical, and head and neck cancers; infectious diseases, including Ebola; and other serious viral, fungal, and bacterial infections. It is also develops high-affinity natural killer product candidates primarily for the treatment of solid tumors, breast cancer, head and neck/squamous, lymphoma, and various cancer; and target activated natural killer product candidates to treat hematological malignancies and solid tumors. NantKwest, Inc. has a co-development agreement with Altor Bio Science Corporation to collaborate on the development of therapeutic applications combining the companyÂ’s proprietary natural killer cells with Altor’s ALT-801 and/or ALT-803 products. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California.
Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.